


Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

1.(currently amended) A compound having the formula



wherein:

R^1 is H, NO_2 , halo, NR^6R^7 , $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{R}^6\text{OC}_{0-6}\text{alkyl}$, R^6CO , R^6OCO or CONR^6R^7 ;

m is 0, 1, 2 or 3;

R^2 is NO_2 , halo, NR^6R^7 , $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, cyano, $\text{R}^6\text{OC}_{0-6}\text{alkyl}$, R^6CO , R^6OCO , R^6CONR^7 , $\text{R}^6\text{R}^7\text{NCO}$, R^8SO_2 , $\text{R}^8\text{SO}_2\text{HN}$, $\text{arylC}_{0-6}\text{alkyl}$ or $\text{heteroarylC}_{0-6}\text{alkyl}$;

R^3 and R^9 are each independently H or $\text{C}_{1-4}\text{alkyl}$;

p is 0, 1 or 2;

n is 0, 2, 3 or 4;

R^5 is $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{6-10}\text{arylC}_{0-6}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkylC}_{0-6}\text{alkyl}$ or $\text{C}_{5-6}\text{heteroarylC}_{0-6}\text{alkyl}$, whereby any aryl, heteroaryl or cycloalkyl may be fused with aryl, heteroaryl, $\text{C}_{3-7}\text{cycloalkyl}$ or $\text{C}_{3-7}\text{heterocycloalkyl}$, and which R^5 may be substituted with one or more A;

A is H, OH, NO_2 , cyano, R^6CO , $\text{R}^6\text{O}(\text{CO})$, halo, $\text{C}_{1-6}\text{alkyl}$, NR^6R^7 , $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{R}^6\text{OC}_{0-6}\text{alkyl}$, $\text{hydroxyC}_{1-6}\text{alkyl}$, R^8SO_2 , $\text{R}^8\text{SO}_2\text{HN}$, $\text{C}_{5-6}\text{arylO}$ or CONR^6R^7 ;

R^6 and R^7 are each independently H or $\text{C}_{1-6}\text{alkyl}$; and

R^8 is NR^6R^7 or $\text{C}_{1-4}\text{alkyl}$,

~~or salts, solvates or solvated salts~~ or a salt, solvate or solvated salt thereof.

2.(currently amended) [[The]] A compound according to claim 1, wherein:

R^1 is H, halo, NR^6R^7 , C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkylO, R^6OC_{0-6} alkyl, R^6CO , R^6OCO or $CONR^6R^7$;

m is 0 or 1;

R^2 is NO_2 , halo, NR^6R^7 , C_{1-6} alkyl, C_{1-6} haloalkyl, cyano, R^6OCO , R^6CONR^7 , R^8SO_2 , R^8SO_2HN or heteroaryl C_{0-6} alkyl;

R^3 and R^9 are each independently H or C_{1-4} alkyl;

p is 0;

n is 0;

R^5 is C_{1-10} alkyl, C_{6-10} aryl C_{0-6} alkyl or C_{5-6} heteroaryl C_{0-6} alkyl, whereby any aryl may be fused with C_{3-7} cycloalkyl or C_{3-7} heterocycloalkyl, and which R^5 may be substituted with one or more A;

A is H, cyano, halo, NO_2 , C_{1-6} alkyl, NR^6R^7 , C_{1-6} haloalkyl, C_{1-6} haloalkylO, R^6OC_{0-6} alkyl, hydroxy C_{1-6} alkyl, R^8SO_2 or C_{5-6} arylO;

R^6 and R^7 are each independently H or C_{1-6} alkyl; and

R^8 is NR^6R^7 or C_{1-4} alkyl,

~~or salts, solvates or solvated salts~~ or a salt, solvate or solvated salt thereof.

3.(currently amended) [[The]] A compound according to claim 1, wherein

R^2 is NO_2 , halo, NR^6R^7 , C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-2} haloalkylO, cyano, R^6OC_{0-4} alkyl, R^6CO , R^6OCO , R^6CONR^7 , R^6R^7NCO , R^8SO_2 , R^8SO_2HN , aryl C_{0-6} alkyl and heteroaryl and wherein

R^6 and R^7 are each independently H or C_{1-4} alkyl and

R^8 is NR^6R^7 or C_{1-3} alkyl.

4.(currently amended) [[The]] A compound according to claim 1, wherein R^2 is [[nitro]] NO_2 .

5.(currently amended) [[The]] A compound according to claim 1, wherein R^5 is phenyl, which may be substituted with one or more A.

6.(currently amended) [[The]] A compound according to claim 5, wherein A is selected from the group ~~comprising~~ consisting of halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and (di)alkylamino.

7.(currently amended) [[The]] A compound according to claim 1, wherein A is selected from the group consisting of fluoro, iodo, chloro, bromo, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, tetrafluoroethoxy, methyl, ethyl, propyl, butyl, hydroxyethyl, cyano, phenoxymethylsulfonyl and dimethylamino.

8.(currently amended) ~~The compounds~~ A compound selected from the group consisting of:

N-(3-Fluoro-4-methoxy-phenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)-acetamide,
N-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Chloro-4-iodophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Chloro-4-methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-(Difluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,5-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)phenyl]acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]acetamide,
N-(4-*tert*-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-(1-Hydroxyethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)phenyl]acetamide,
N-(3-Chlorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-Hexyl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,4-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(4-Cyanophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2-Bromobenzyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,
N-(4-Methylpyridin-2-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Cyanophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,5-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3,4-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3,4,5-trimethoxyphenyl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethoxy)phenyl]acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3-phenoxyphenyl)acetamide,
N-(4-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2-Fluoro-4-iodophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[2-(trifluoromethoxy)phenyl]acetamide,
N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(2-phenoxyphenyl)acetamide,
N-(4-Bromo-2-fluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[4-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)benzyl]acetamide,
N-(4-*tert*-Butylbenzyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2,3-dihydro-1*H*-inden-5-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)benzyl]acetamide,
N-(4-Isopropylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,4-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-1,3-Benzodioxol-5-yl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-Bromo-4-(trifluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Fluoro-2-methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,5-dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]propanamide,
N-(3,5-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-(3-methoxyphenyl)acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(4-methylphenyl)acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(2,3-dihydro-1*H*-inden-5-yl)acetamide,

2-(7-Methyl-1H-benzimidazol-1-yl)-N-(4-methylphenyl)acetamide,
N-(3,5-Dimethoxyphenyl)-2-(7-methyl-1H-benzimidazol-1-yl)acetamide,
2-(7-Methyl-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
N-(2,3-Dihydro-1H-inden-5-yl)-2-(7-methyl-1H-benzimidazol-1-yl)acetamide,
Methyl 1-{2-[(3,4-dimethylphenyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate,
Methyl 1-[2-(2,3-dihydro-1H-inden-5-ylamino)-2-oxoethyl]-1H-benzimidazole-7-carboxylate,
Methyl 1-{2-[(4-*tert*-butylbenzyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate,
Methyl 1-(2-{[3-methoxy-5-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-1H-benzimidazole-7-carboxylate,
Methyl 1-{2-[(3,5-dimethoxyphenyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate,
N-(3,5-Dimethoxyphenyl)-2-{7-[(dimethylamino)sulfonyl]-1H-benzimidazol-1-yl}acetamide,
2-{7-[(Dimethylamino)sulfonyl]-1H-benzimidazol-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide,
N-(3,5-Dimethoxyphenyl)-2-[7-(propylsulfonyl)-1H-benzimidazol-1-yl]acetamide,
2-[7-(Propylsulfonyl)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-[7-(methylsulfonyl)-1H-benzimidazol-1-yl]acetamide,
N-(3,5-Dimethoxyphenyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
N-(3,4-Dimethylphenyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
N-(4-*tert*-Butylbenzyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
N-(2,3-Dihydro-1H-inden-5-yl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
2-(7-Cyano-1H-benzimidazol-1-yl)-N-(3,5-dimethoxyphenyl)acetamide,
2-(7-Cyano-1H-benzimidazol-1-yl)-N-(3-methoxyphenyl)acetamide,
2-(7-Cyano-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Cyano-1H-benzimidazol-1-yl)-N-(2,3-dihydro-1H-inden-5-yl)acetamide,
N-(2,3-Dihydro-1H-inden-5-yl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
N-(3,5-Dimethoxyphenyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
N-(4-*tert*-Butylbenzyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
2-(7-Amino-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Acetylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
2-{7-[(Methylsulfonyl)amino]-1H-benzimidazol-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide,

2-[7-(Dimethylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Isopropylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
N-(3,5-Dimethoxyphenyl)-2-[7-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl]acetamide,
and
2-(6,7-Difluoro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
~~or salts, solvates or solvated salts~~ or a salt, solvate or solvated salt thereof.

9.(currently amended) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to ~~any one of claims 1 to 8~~ claim 1, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

10. - 17.(cancelled)

18.(currently amended) A method of ~~treatment of~~ treating VR1 mediated disorders, ~~and for treatment of~~ acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, and respiratory diseases, comprising ~~administering~~ administering to a mammal, ~~including man~~ in need of such treatment, a therapeutically effective amount of ~~the compounds of formula I, according to any one of claims 1 to 8~~ a compound according to claim 1.

19.(currently amended) ~~Compounds selected from the group consisting~~ A compound selected from the group consisting of:

(7-Nitro-1H-benzimidazol-1-yl)acetonitrile,
(7-Nitro-1H-benzimidazol-1-yl)acetic acid,
2-(7-Nitro-1H-benzimidazol-1-yl)propanenitrile,
2-(7-nitro-1H-benzimidazol-1-yl)propanoic acid,
2-[(2-Bromo-6-nitrophenyl)amino]ethanol,
2-[(2-Amino-6-bromophenyl)amino]ethanol,

2-(7-Bromo-1*H*-benzimidazol-1-yl)ethanol,
(7-Bromo-1*H*-benzimidazol-1-yl)acetic acid,
8-Chloro-3-oxo-3,4-dihydroquinoxaline-1(2*H*)-carbaldehyde,
2-[(2-Amino-6-chlorophenyl)amino]ethanol,
2-(7-Chloro-1*H*-benzimidazol-1-yl)ethanol,
(7-Chloro-1*H*-benzimidazol-1-yl)acetic acid,
(2-Methyl-6-nitrophenyl)formamide,
Ethyl *N*-formyl-*N*-(2-methyl-6-nitrophenyl)glycinate,
Ethyl *N*-(2-amino-6-methylphenyl)-*N*-formylglycinate,
(7-Methyl-1*H*-benzimidazol-1-yl)acetic acid,
2-[(2-Hydroxyethyl)amino]-3-nitrobenzoic acid,
Methyl 2-[(2-hydroxyethyl)amino]-3-nitrobenzoate,
Methyl 1-(2-hydroxyethyl)-1*H*-benzimidazole-7-carboxylate,
3-Carboxymethyl-3*H*-benzimidazole-4-carboxylic acid methyl ester,
2-Chloro-*N,N*-dimethyl-3-nitrobenzenesulfonamide,
2-[(2-Hydroxyethyl)amino]-*N,N*-dimethyl-3-nitrobenzenesulfonamide,
3-Amino-2-[(2-hydroxyethyl)amino]-*N,N*-dimethylbenzenesulfonamide,
1-(2-Hydroxyethyl)-*N,N*-dimethyl-1*H*-benzimidazole-7-sulfonamide,
(7-Dimethylsulfamoyl-benzimidazol-1-yl)-acetic acid,
2-Chloro-1-nitro-3-(propylsulfonyl)benzene,
2-{[2-Nitro-6-(propylsulfonyl)phenyl]amino}ethanol,
2-{[2-Amino-6-(propylsulfonyl)phenyl]amino}ethanol,
[7-(Propylsulfonyl)-1*H*-benzimidazol-1-yl]acetic acid,
[7-(Methylsulfonyl)-1*H*-benzimidazol-1-yl]acetic acid,
2-(7-(Methylsulfonyl)-1*H*-benzimidazol-1-yl)-ethanol,
2-{[2-Nitro-6-(trifluoromethyl)phenyl]amino}ethanol,
2-{[2-amino-6-(trifluoromethyl)phenyl]amino}ethanol,
2-[7-(Trifluoromethyl)-1*H*-benzimidazol-1-yl]ethanol,
[7-(Trifluoromethyl)-1*H*-benzimidazol-1-yl]acetic acid,
2-[(2-hydroxyethyl)amino]-3-nitrobenzonitrile,
1-(2-hydroxyethyl)-1*H*-benzimidazole-7-carbonitrile,
(7-Cyano-1*H*-benzimidazol-1-yl)acetic acid,
2-[(2-Fluoro-6-nitrophenyl)amino]ethanol,

2-(7-Fluoro-1*H*-benzoimidazol-1-yl)ethanol, and
(7-Fluoro-1*H*-benzimidazol-1-yl)acetic acid[[],] .

20.(cancelled)

21.(currently amended) ~~The compounds selected from the group consisting of~~ A
compound selected from the group consisting of:

2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]propanamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3-chloro-4-fluorophenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3-fluoro-4-methylphenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3,4-difluorophenyl)acetamide,
2-(4-Methyl-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4,5-Difluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(dimethylamino)phenyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(4-chlorobenzyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
3-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)propanamide,
4-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)butanamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(2-methyl-1,3-benzothiazol-5-yl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4-Amino-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-Fluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6-Fluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1*H*-Benzimidazol-1-yl)-*N*-heptylacetamide,
~~or salts, solvates or solvated salts~~ or a salt, solvate or solvated salt thereof.

22.(currently amended) ~~The compounds selected from the group consisting A~~
compound selected from the group consisting of:

2-(1*H*-Indol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-Fluoro-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1-Methyl-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
~~or salts, solvates or solvated salts~~ or a salt, solvate or solvated salt thereof.

23.(new) The method according to claim 18, wherein said VR1 mediated disorder is selected from: arthritis, fibromyalgia, low back pain, post-operative pain, visceral pain, chronic pelvic pain, cystitis, irritable bowel syndrome, pancreatitis, ischemia, sciatica, diabetic neuropathy, multiple sclerosis, interstitial cystitis and pain related to interstitial cystitis, HIV neuropathy, asthma, cough and inflammatory bowel disease, gastro-esophageal reflux disease, psoriasis, cancer, emesis, urinary incontinence or hyperactive bladder.

24.(new) The method according to claim 18, wherein said mammal is a human.